Inside, during a meal once or twice a day. The therapeutic efficacy of the and its side effects are dose dependent and vary between patients. This requires individual dose adjustment during therapy. Treatment with andriol dosage should be initiated at a dose of 0.5 mg / kg per day. In most patients, the dose ranges from 0.5 to 1.0 mg / kg of body weight per day. Patients with very severe disease or with body acne may require higher daily doses – up to 2.0 mg / kg. It is proved that the frequency of remission and relapse prevention by using optimal course dose of , so the duration of therapy in individual patients varies depending on the daily dose. Complete remission of acne is often possible to achieve at 16-24 weeks of treatment. Patients undergoing very bad the recommended dose, treatment may be continued at a lower dose, but to hold it longer. In most patients, the acne disappear completely after a single course of treatment. With explicit recurrence shows a second course of treatment with Roaccutane ® in the same daily dose and the exchange rate as the first. As improvement may continue for up to 8 weeks after discontinuation of therapy, a second course should be administered no earlier than the end of this period.
Dosing in special cases,
patients with severe renal failure treatment should be initiated at a lower dose (e.g. 10 mg / day), and then increased to 1 mg / kg / day or maximum tolerated (not to exceed the maximum daily dose of 1 mg / kg). The daily dose should be rounded down to the nearest whole number of smaller capsules.
Most side effects of the drug andriol dosagedose dependent. As a rule, the appointment of the recommended doses and the risk-benefit ratio, taking into account the severity of the disease, it is acceptable to the patient. Usually, side effects are reversible after dose adjustment or discontinuation of the drug, but some may persist after cessation of treatment. Symptoms associated with hypervitaminosis A: dry skin, mucous membranes, including lips (cheilitis), the nasal cavity (hemorrhage), hypopharynx (hoarseness), eyes (conjunctivitis, reversible corneal opacities and intolerance to contact lenses). Skin and appendages: rash, pruritus, facial erythema / dermatitis, sweating, pyogenic granuloma, paronychia , onychodystrophy, increased proliferation of granulation tissue, persistent hair thinning, reversible hair loss, fulminant form of acne, hirsutism, hyperpigmentation, photosensitivity, photoallergy, light injuries to the skin, peeling of the skin of the palms and soles.
Early treatment can occur exacerbation of acne that persists for several weeks. Musculoskeletal system: muscle pain with increased activity of creatine phosphokinase (CPK) in serum or without it, joint pain, hyperostosis, arthritis, calcification of ligaments and tendons, a decrease in bone density , premature closure of epiphyseal growth zones, other bone changes, tendinitis. The central nervous system and mental health: behavioral disorders, depression, suicide attempts, suicide, psychosis, excessive fatigue, headache, increased intracranial pressure ( “brain pseudotumor” headache , nausea, vomiting, blurred vision, swelling of the optic nerve), seizures. sensory organs: violation of visual acuity, photophobia, violation of dark adaptation (decrease in visual twilight vision), disturbance of color vision (passing after drug discontinuation), lenticular cataract, keratitis, blepharitis, conjunctivitis, eye irritation, xerophthalmia, impaired hearing at certain frequencies of sound.
Gastrointestinal tract: nausea, diarrhea, inflammatory bowel disease (colitis, ileitis), bleeding, dryness of the oral mucosa, bleeding from the gums, inflammation of the gums; pancreatitis (especially hypertriglyceridemia with concomitant higher than 800 mg / dl), including fatal. Transient and reversible increases in liver transaminases, hepatitis. In many of these cases, the changes do not go beyond the limit of normal and returned to baseline parameters during treatment, but in some cases there was a need to reduce the dose or cancel andriol dosage. Respiratory: bronchospasm (more frequently in patients with bronchial asthma in history). Blood System: anemia, decreased hematocrit, leukopenia, neutropenia, increase or decrease the number of platelets, increased erythrocyte sedimentation rate (ESR). Laboratory findings: hypertriglyceridemia, hypercholesterolemia, hyperuricemia, decrease in the concentration of high-density lipoprotein hyperglycemia. During the administration cases of new-onset diabetes mellitus have been reported. In some patients, particularly those engaged in intense physical activity, are described isolated cases increase CK activity in serum. The immune system: local or systemic infections caused by Gram-positive pathogens (Staphylococcus aureus). Others: lymphadenopathy, hematuria, proteinuria, vasculitis (Wegener’s granulomatosis, hypersensitivity vasculitis ), systemic hypersensitivity reactions, glomerulonephritis, pain in the back.